Superworth

Tenax Therapeutics EV/EBIT TENX

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2021.

Today, Oct 23, 2026
n/m
an operating loss
Last meaningful
0.0×
Feb 2023
Peer median
3.2×

Tenax Therapeutics has no meaningful EV/EBIT today: it made an operating loss of $68.6M over the last twelve months.

It was last meaningful in Feb 2023, at 0.0×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
20230.0×0.0×0.2×
20220.1×0.0×1.2×
20211.4×1.4×3.9×

Against its peers

Companies in Drug Manufacturers - General nearest Tenax Therapeutics' size, closest first, today.

CompanyEV/EBIT
TENXTenax Therapeuticsn/m
SPROSpero Therapeutics2.1×
LFVNLifevantage9.6×
ATNMActinium Pharmaceuticals1.2×
NATRNatures Sunshine Products5.2×
ARVNArvinasn/m
PBYIPuma Biotechnology15.6×
IRWDIronwood Pharmaceuticals3.5×
ZVRAZevra Therapeutics2.9×
CRMDCorMedix2.3×
Peer median3.2×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Tenax Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.